Literature DB >> 23273967

Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt.

Danny Altmann, Abraham Aseffa, Margaret Bash, Nicole Basta, Ray Borrow, Claire Broome, Dominique Caugant, Tom Clark, Jean-Marc Collard, Mamoudou Djingarey, David Goldblatt, Brian Greenwood, Ulla Griffiths, Rana Hajjeh, Musa Hassan-King, Stephane Hugonnet, Ann Marie Kimball, Marc LaForce, Calman MacLennan, Martin C J Maiden, Olivier Manigart, Leonard Mayer, Nancy Messonnier, Jennifer Moisi, Katie Moore, Daugla Doumagoum Moto, Judith Mueller, Maria Nascimento, Stephen Obaro, Rasmata Ouedraogo, Anne-Laure Page, Willima Perea, Gerd Pluschke, Mari-Pierre Preziosi, Samba Sow, David Stephens, James Stuart, Madeleiene Thomson, Sylvestre Tiendrebeogo, Jean-Francois Trape, Guy Vernet.   

Abstract

For over 100 years, large epidemics of meningococcal meningitis have occurred every few years in areas of the African Sahel and sub-Sahel known as the African meningitis belt. Until recently, the main approach to the control of these epidemics has been reactive vaccination with a polysaccharide vaccine after an outbreak has reached a defined threshold and provision of easy access to effective treatment but this approach has not prevented the occurrence of new epidemics. Meningococcal conjugate vaccines, which can prevent meningococcal carriage and thus interrupt transmission, may be more effective than polysaccharide vaccines at preventing epidemics. Because the majority of African epidemics have been caused by serogroup A meningococci, a serogroup A polysaccharide/tetanus toxoid protein conjugate vaccine (PsA-TT) has recently been developed. Results from an initial evaluation of the impact of this vaccine on meningococcal disease and meningococcal carriage in Burkina Faso have been encouraging. To review how the research agenda for meningococcal disease in Africa has been changed by the advent of PsA-TT and to define a new set of research priorities for study of meningococcal infection in Africa, a meeting of 41 scientists was held in Dakar, Senegal on April 24th and 25th 2012. The research recommendations developed during the course of this meeting are presented in this paper. The need for enhanced surveillance for meningitis in defined populations with good diagnostic facilities in African countries at risk of epidemics was identified as the highest priority. This is needed to determine the duration of protection against serogroup A meningococcal disease provided by PsA-TT and to determine the risk of disease and carriage caused by meningococci of other serogroups. Other research areas given high priority included identification and validation of serological correlates of protection against meningococcal disease and carriage, development of improved methods for detecting carriage and epidemiological studies aimed at determining the reasons underlying the peculiar epidemiology of meningococcal disease in the African meningitis belt. Minutes and working papers from the meeting are provided in supplementary tables and some of the presentations made at the meeting are available on the MenAfriCar consortium website (www.menafricar.org) and on the web site of the Centers for Disease Control (www.cdc.gov).
Copyright © 2013. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23273967      PMCID: PMC3988351          DOI: 10.1016/j.vaccine.2012.12.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Editorial: 100 years of epidemic meningitis in West Africa - has anything changed?

Authors:  Brian Greenwood
Journal:  Trop Med Int Health       Date:  2006-06       Impact factor: 2.622

2.  Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger.

Authors:  Pascal Boisier; Pierre Nicolas; Saacou Djibo; Muhamed-Kheir Taha; Isabelle Jeanne; Halima Boubacar Maïnassara; Bernard Tenebray; Kiari Kaka Kairo; Dario Giorgini; Suzanne Chanteau
Journal:  Clin Infect Dis       Date:  2007-01-25       Impact factor: 9.079

Review 3.  Systems vaccinology: learning to compute the behavior of vaccine induced immunity.

Authors:  Helder I Nakaya; Shuzhao Li; Bali Pulendran
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2011-10-19

4.  Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.

Authors:  Paul A Kristiansen; Fabien Diomandé; Absatou Ky Ba; Idrissa Sanou; Abdoul-Salam Ouédraogo; Rasmata Ouédraogo; Lassana Sangaré; Denis Kandolo; Flavien Aké; Inger Marie Saga; Thomas A Clark; Lara Misegades; Stacey W Martin; Jennifer Dolan Thomas; Sylvestre R Tiendrebeogo; Musa Hassan-King; Mamoudou H Djingarey; Nancy E Messonnier; Marie-Pierre Préziosi; F Marc Laforce; Dominique A Caugant
Journal:  Clin Infect Dis       Date:  2012-10-19       Impact factor: 9.079

5.  Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

Authors:  Samba O Sow; Brown J Okoko; Aldiouma Diallo; Simonetta Viviani; Ray Borrow; George Carlone; Milagritos Tapia; Adebayo K Akinsola; Pascal Arduin; Helen Findlow; Cheryl Elie; Fadima Cheick Haidara; Richard A Adegbola; Doudou Diop; Varsha Parulekar; Julie Chaumont; Lionel Martellet; Fatoumata Diallo; Olubukola T Idoko; Yuxiao Tang; Brian D Plikaytis; Prasad S Kulkarni; Elisa Marchetti; F Marc LaForce; Marie-Pierre Preziosi
Journal:  N Engl J Med       Date:  2011-06-16       Impact factor: 91.245

6.  Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.

Authors:  Ryan T Novak; Jean Ludovic Kambou; Fabien Vk Diomandé; Tiga F Tarbangdo; Rasmata Ouédraogo-Traoré; Lassana Sangaré; Clement Lingani; Stacey W Martin; Cynthia Hatcher; Leonard W Mayer; F Marc Laforce; Fenella Avokey; Mamoudou H Djingarey; Nancy E Messonnier; Sylvestre R Tiendrébéogo; Thomas A Clark
Journal:  Lancet Infect Dis       Date:  2012-07-18       Impact factor: 25.071

Review 7.  Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.

Authors:  Mamoudou H Djingarey; Rodrigue Barry; Mete Bonkoungou; Sylvestre Tiendrebeogo; Rene Sebgo; Denis Kandolo; Clement Lingani; Marie-Pierre Preziosi; Patrick L F Zuber; William Perea; Stéphane Hugonnet; Nora Dellepiane de Rey Tolve; Carole Tevi-Benissan; Thomas A Clark; Leonard W Mayer; Ryan Novak; Nancy E Messonier; Monique Berlier; Desire Toboe; Deo Nshimirimana; Richard Mihigo; Teresa Aguado; Fabien Diomandé; Paul A Kristiansen; Dominique A Caugant; F Marc Laforce
Journal:  Vaccine       Date:  2012-05-30       Impact factor: 3.641

8.  Manson Lecture. Meningococcal meningitis in Africa.

Authors:  B Greenwood
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Jul-Aug       Impact factor: 2.184

Review 9.  Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).

Authors:  Carl E Frasch; Marie-Pierre Preziosi; F Marc LaForce
Journal:  Hum Vaccin Immunother       Date:  2012-04-12       Impact factor: 3.452

Review 10.  Systematic review: Impact of meningococcal vaccination on pharyngeal carriage of meningococci.

Authors:  Stephanie Dellicour; Brian Greenwood
Journal:  Trop Med Int Health       Date:  2007-10-24       Impact factor: 2.622

View more
  23 in total

1.  Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.

Authors:  Flor M Munoz; Leonard E Weisman; Jennifer S Read; George Siberry; Karen Kotloff; Jennifer Friedman; Rosemary D Higgins; Heather Hill; Harry Seifert; Mirjana Nesin
Journal:  Clin Infect Dis       Date:  2014-12-15       Impact factor: 9.079

Review 2.  Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection.

Authors:  E David McIntosh; Victor Carey; Daniela Toneatto; Peter Dull; James Wassil
Journal:  Ther Adv Vaccines       Date:  2015-01

3.  Analysis of novel meningococcal vaccine formulations.

Authors:  Susu M Zughaier
Journal:  Hum Vaccin Immunother       Date:  2017-04-10       Impact factor: 3.452

4.  Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study.

Authors:  S M Niaz Arifin; Christoph Zimmer; Caroline Trotter; Anaïs Colombini; Fati Sidikou; F Marc LaForce; Ted Cohen; Reza Yaesoubi
Journal:  Med Decis Making       Date:  2019-07-03       Impact factor: 2.583

5.  The burden of meningococcal meningitis in the African Meningitis Belt, from 2009 to 2014: a trend analysis.

Authors:  Anelisa Jaca; Alison Beriliy Wiyeh; Evanson Zondani Sambala; Charles Shey Wiysonge
Journal:  Pan Afr Med J       Date:  2021-05-20

6.  Central nervous system infections in travelers.

Authors:  H L Kirsch; K T Thakur; G L Birbeck
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.663

7.  Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.

Authors:  Nicole E Basta; Ray Borrow; Abdoulaye Berthe; Awa Traoré Eps Dembélé; Uma Onwuchekwa; Kelly Townsend; Rahamatou M Boukary; Lesley Mabey; Helen Findlow; Xilian Bai; Samba O Sow
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

8.  Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.

Authors:  Aldiouma Diallo; Samba O Sow; Olubukola T Idoko; Siddhivinayak Hirve; Helen Findlow; Marie-Pierre Preziosi; Cheryl Elie; Prasad S Kulkarni; Varsha Parulekar; Bou Diarra; Fadima Cheick Haidara; Fatoumata Diallo; Milagritos Tapia; Adebayo K Akinsola; Richard A Adegbola; Ashish Bavdekar; Sanjay Juvekar; Julie Chaumont; Lionel Martellet; Elisa Marchetti; Marc F LaForce; Brian D Plikaytis; Godwin C Enwere; Yuxiao Tang; Ray Borrow; George Carlone; Simonetta Viviani
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

9.  Methods for identifying Neisseria meningitidis carriers: a multi-center study in the African meningitis belt.

Authors:  Nicole E Basta; James M Stuart; Maria C Nascimento; Olivier Manigart; Caroline Trotter; Musa Hassan-King; Daniel Chandramohan; Samba O Sow; Abdoulaye Berthe; Ahmed Bedru; Yenenesh K Tekletsion; Jean-Marc Collard; Jean-François Jusot; Aldiouma Diallo; Hubert Basséne; Doumagoum M Daugla; Khadidja Gamougam; Abraham Hodgson; Abudulai A Forgor; Babatunji A Omotara; Galadima B Gadzama; Eleanor R Watkins; Lisa S Rebbetts; Kanny Diallo; Noel S Weiss; M Elizabeth Halloran; Martin C J Maiden; Brian Greenwood
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

10.  Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].

Authors:  D M Daugla; J P Gami; K Gamougam; N Naibei; L Mbainadji; M Narbé; J Toralta; B Kodbesse; C Ngadoua; M E Coldiron; F Fermon; A-L Page; M H Djingarey; S Hugonnet; O B Harrison; L S Rebbetts; Y Tekletsion; E R Watkins; D Hill; D A Caugant; D Chandramohan; M Hassan-King; O Manigart; M Nascimento; A Woukeu; C Trotter; J M Stuart; McJ Maiden; B M Greenwood
Journal:  Lancet       Date:  2013-09-12       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.